ABT vs ARQ · P/E 25, rev $44.33B vs rev $58.9M
Abbott Laboratories (ABT) versus Arq Inc (ARQ) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
Arq Inc (ARQ) is a pollution & treatment controls company listed on US.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported ARQ revenue for 2026-06-30 was $58.9M. Net income was -$1.9M. ARQ currently screens at market cap $230.5M.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. ARQ currently screens at market cap $230.5M.
Not investment advice. Open the ABT and ARQ stock pages for the full models.
Not investment advice.